中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
19期
2914-2916
,共3页
胃肿瘤%放化疗,辅助%基质金属蛋白酶9%血管内皮生长因子类
胃腫瘤%放化療,輔助%基質金屬蛋白酶9%血管內皮生長因子類
위종류%방화료,보조%기질금속단백매9%혈관내피생장인자류
Stomach neoplasms%Chemoradiotherapy,adjuvant%Matrix metalloproteinase 9%Vascular endothe-lial growth factors
目的：探讨替吉奥胶囊联合奥沙利铂新辅助化疗对进展期胃癌患者基质金属蛋白酶-9（MMP-9）和血管内皮生长因子（VEGF）的影响。方法92例进展期胃癌患者按照数字表法随机分为两组，观察组46例，对照组46例，均采用术前新辅助化疗，观察组采用替吉奥胶囊联合奥沙利铂化疗，对照组采用卡培他滨联合奥沙利铂化疗。采用免疫组化测定胃癌组织中MMP-9和VEGF的表达。结果化疗后对照组总有效率为60．9％，观察组总有效率为80．4％，观察组总有效率明显高于对照组（χ2＝6．42，P＜0．05）。两组患者贫血、血小板减少、肝功能损害、肾功能损害、恶心呕吐的发生率比较差异无统计学意义（χ2＝1．52、0．96、2.06、0．00、1．28，均P＞0．05），观察组患者白细胞减少、神经毒性少于对照组（χ2＝5．68、4．18，均P＜0．05）。对照组化疗前VEGF和MMP-9的表达阳性率分别为93．5％、78．3％，观察组分别为89．1％和82．6％，两组差异无统计学意义（χ2＝2．12、2，72，均P ＞0．05）。化疗后对照组 VEGF 和 MMP-9的表达阳性率分别为45.7％、41.3％，观察组VEGF和MMP-9的表达阳性率分别为23．9％和21．7％，两组化疗后VEGF和MMP-9的表达阳性率均明显小于化疗前（χ2＝4．72、4．08、10．14、9．84，P＜0．05，P＜0．01），观察组比对照组降低更明显（χ2＝5．14、4.72，均P＜0．05）。结论替吉奥胶囊联合奥沙利铂新辅助化疗可以明显降低进展期胃癌患者MMP-9和VEGF的表达。
目的：探討替吉奧膠囊聯閤奧沙利鉑新輔助化療對進展期胃癌患者基質金屬蛋白酶-9（MMP-9）和血管內皮生長因子（VEGF）的影響。方法92例進展期胃癌患者按照數字錶法隨機分為兩組，觀察組46例，對照組46例，均採用術前新輔助化療，觀察組採用替吉奧膠囊聯閤奧沙利鉑化療，對照組採用卡培他濱聯閤奧沙利鉑化療。採用免疫組化測定胃癌組織中MMP-9和VEGF的錶達。結果化療後對照組總有效率為60．9％，觀察組總有效率為80．4％，觀察組總有效率明顯高于對照組（χ2＝6．42，P＜0．05）。兩組患者貧血、血小闆減少、肝功能損害、腎功能損害、噁心嘔吐的髮生率比較差異無統計學意義（χ2＝1．52、0．96、2.06、0．00、1．28，均P＞0．05），觀察組患者白細胞減少、神經毒性少于對照組（χ2＝5．68、4．18，均P＜0．05）。對照組化療前VEGF和MMP-9的錶達暘性率分彆為93．5％、78．3％，觀察組分彆為89．1％和82．6％，兩組差異無統計學意義（χ2＝2．12、2，72，均P ＞0．05）。化療後對照組 VEGF 和 MMP-9的錶達暘性率分彆為45.7％、41.3％，觀察組VEGF和MMP-9的錶達暘性率分彆為23．9％和21．7％，兩組化療後VEGF和MMP-9的錶達暘性率均明顯小于化療前（χ2＝4．72、4．08、10．14、9．84，P＜0．05，P＜0．01），觀察組比對照組降低更明顯（χ2＝5．14、4.72，均P＜0．05）。結論替吉奧膠囊聯閤奧沙利鉑新輔助化療可以明顯降低進展期胃癌患者MMP-9和VEGF的錶達。
목적：탐토체길오효낭연합오사리박신보조화료대진전기위암환자기질금속단백매-9（MMP-9）화혈관내피생장인자（VEGF）적영향。방법92례진전기위암환자안조수자표법수궤분위량조，관찰조46례，대조조46례，균채용술전신보조화료，관찰조채용체길오효낭연합오사리박화료，대조조채용잡배타빈연합오사리박화료。채용면역조화측정위암조직중MMP-9화VEGF적표체。결과화료후대조조총유효솔위60．9％，관찰조총유효솔위80．4％，관찰조총유효솔명현고우대조조（χ2＝6．42，P＜0．05）。량조환자빈혈、혈소판감소、간공능손해、신공능손해、악심구토적발생솔비교차이무통계학의의（χ2＝1．52、0．96、2.06、0．00、1．28，균P＞0．05），관찰조환자백세포감소、신경독성소우대조조（χ2＝5．68、4．18，균P＜0．05）。대조조화료전VEGF화MMP-9적표체양성솔분별위93．5％、78．3％，관찰조분별위89．1％화82．6％，량조차이무통계학의의（χ2＝2．12、2，72，균P ＞0．05）。화료후대조조 VEGF 화 MMP-9적표체양성솔분별위45.7％、41.3％，관찰조VEGF화MMP-9적표체양성솔분별위23．9％화21．7％，량조화료후VEGF화MMP-9적표체양성솔균명현소우화료전（χ2＝4．72、4．08、10．14、9．84，P＜0．05，P＜0．01），관찰조비대조조강저경명현（χ2＝5．14、4.72，균P＜0．05）。결론체길오효낭연합오사리박신보조화료가이명현강저진전기위암환자MMP-9화VEGF적표체。
Objective To study DeFazio capsules oxaliplatin neoadjuvant chemotherapy on matrix metallo-proteinase-9 ( MMP-9 ) and vascular endothelial growth factor ( VEGF ) in patients with advanced gastric cancer . Methods 92 patients with advanced gastric cancer were randomly divided into the two groups ,the observation group ( n=46 ) and the control group ( n=46 ) .Both two groups were used neoadjuvant chemotherapy , DeFazio capsules oxaliplatin chemotherapy for the observation group and capecitabine oxaliplatin chemotherapy for the control group . Expression of MMP-9 and VEGF was determined by immunohistochemistry in gastric cancer tissues .Results After chemotherapy,the total effective rate was 60.9%in the control group and 80.4%in the observation group.The total effective rate of the observation group was significantly higher (χ2 =6.42,P<0.05).The anemia,thrombocyto-penia,hepatic dysfunction ,renal dysfunction ,the incidence of nausea and vomiting had no significant differences be-tween the two groups (χ2 =1.52,0.96,2.06,0.00,1.28,all P>0.05).Neutropenia,neurotoxicity in the observation group were less than the control group (χ2 =5.68,4.18,all P<0.05).Before chemotherapy,the positive rates of VEGF and MMP-9 expression in the control group were 93.5%,78.3%.Those of the observation group were 89.1%and 82.6%,respectively,the differences were not significant (χ2 =2.12,2,72,all P>0.05).After the chemothera-py,the positive expression rates of VEGF and MMP-9 in the control group were 45.7%,41.3%,respectively.Those of the observation group were 23.9%and 21.7%,respectively.VEGF and MMP-9 positive expression rates were sig-nificantly lower than before chemotherapy (χ2 =4.72,4.08,10.14,9.84,P<0.05,P<0.01).The observation group was significantly lower than the control group (χ2 =5.14,4.72,all P<0.05).Conclusion DeFazio capsules oxali-platin neoadjuvant chemotherapy can decrease MMP-9 and VEGF expression in patients with advanced gastric cancer .
